Navigation Links
Genetic and Proteomic Advances Pave the Way for Next-Generation Leukemia Therapies
Date:12/10/2011

SAN DIEGO, Dec. 10, 2011 /PRNewswire-USNewswire/ -- Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology. 

"While recent discoveries during the past several decades have paved the way for a much better understanding of how the proteins affecting cancer cells can determine response or resistance to treatment, more progress needs to be made," said Martin S. Tallman, MD, moderator of the press conference and Chief of the Leukemia Service at Memorial Sloan-Kettering Cancer Center in New York. "The abstracts discussed today represent important steps toward targeting these proteins with effective therapies that will make a meaningful difference in the lives of leukemia patients."

This press conference will take place on Saturday, December 10, at 9:30 a.m. PST.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old: A Prospective Randomized Phase 3 Trial from the Acute Leukemia French Association (ALFA) [Abstract 6]

Results from a Phase III clinical trial of monoclonal antibody gemtuzumab ozogamicin (GO) find that the investigational therapy may be a promising option when used in relatively low, frequently repeated doses in conjunction with standard chemotherapy to treat older adults with acute myeloid leukemia (AML).

Chemotherapy has long been the standard of care for induction in patients with AML, an
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Signal Genetics Announces Launch of Next Generation Genetic Multiple Myeloma Predictive Testing Product-MyPRS Plus™
2. VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures
3. Abbotts Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
4. Novel New Dog DNA Test Turns Breeders Into Genetic Matchmakers
5. Genetic Profile Identified for Alzheimers Patients Showing Heightened Response to Acceras Breakthrough Product Axona®
6. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
7. American College of Medical Genetics Applauds HHS Secretarys Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease
8. Ambry Genetics Announces Launch of Their CancerArray™ Product and Services Utilizing aCGH Technology
9. The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977
10. Genetic Testing Can Help the US Cut Costs and Improve Health Care
11. Metamark Genetics Announces Cancer Cell Study Highlighting Discovery of Key Molecules that Drive Progression of Malignant Melanoma in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  Wrightington, Wigan and Leigh ... MDRX ) are delighted to announce WWL,s decision to ... information system. The system will be implemented across all ... WWL delivers healthcare in the future. ... on-time and on-budget system implementations as well as its ...
(Date:9/30/2014)... STUDY OBJECTIVES The objective of ... an overview of the current and future characteristics ... key objective is to present a comprehensive analysis ... important tool in the treatment of various diseases. ... within the protein therapeutics market, which includes peptide ...
(Date:9/30/2014)... 2014  According to their CEO, Rob ... trials is going through a complete transformation with ... of the current clinical trial management process isn,t ... clinical trials, which will ultimately drive the prescription ... company has been recognized by the National Cancer ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2
... Ind., Nov. 3, 2011 Zimmer Holdings, Inc. (NYSE: ... Anterior Cervical Plate System at the 26th North American ... a generous graft window and narrow waist providing clinicians with ... has a low profile (less than 2mm) which clinical literature ...
... PERKASIE, Pa., Nov. 3, 2011 A new company ... customers for implantable medical devices.  US BioDesign, located in ... medical device OEM firms to broaden the company,s breadth ... founders, Tom Molz – CEO and Skott Greenhalgh – ...
Cached Medicine Technology:Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 2Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 3Newly Launched US BioDesign to Provide OEM Development/Manufacturing Services to Medical Device Customers 2
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... WASHINGTON, D.C. and ATLANTA (PRWEB) October 01, ... and information security executive networking and relationship-marketing ... the 2014 Information Security Executive® and Project ... Executives include top-ranking decision makers representing organizations ... and academics. Projects include large-scale technology endeavors ...
(Date:10/1/2014)... finding from Duke Medicine suggests that some people who ... be hard-wired to gain weight when exposed to chronic ... estimated 13 percent of people, all of whom are ... could help them reduce heart disease with simple interventions ... , "Genetic susceptibility, psychosocial stress and metabolic factors act ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... 2011)Approximately 10-20 percent of prostate cancer patients have a family ... that are used to evaluate the extent and aggressiveness of ... the Prostate Specific Antigen Level (PSA), Gleason score (GS) from ... However, men with a family history of prostate cancer have ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Smokers have ... are more likely than men to suffer complications after a ... data on 3,588 patients admitted to the University of Michigan ... attack. About 24 percent of the patients were current smokers. ...
... A tracheostomy performed within the first seven days after a ... to a team of Penn State College of Medicine researchers. ... chance of surviving when admitted to the hospital. A ... neck directly into the trachea to allow unimpeded breathing. (A ...
... Therapeutics will be held from Nov. 12-16, 2011, at ... This unique conference combines the efforts of the American ... the European Organisation for the Research and Treatment of ... to focus exclusively on issues of drug development as ...
... New Tool That Helps Identify Prostate Cancer Patients with ... (October 4, 2011)After a prostate cancer patient receives radiation ... antigen, or PSA, in his blood. An increase in ... of the cancer,s return to the prostate. Fox Chase ...
... video games, already known to improve motor function in,recovering ... in intensive care units (ICU), new research from Johns,Hopkins ... Journal of Critical Care ,researchers studied the safety ... therapy in the ICU. "Patients admitted to our ...
Cached Medicine News:Health News:More aggressive treatment not necessary for men with a family history of prostate cancer 2Health News:Earlier tracheostomies result in better patient outcomes 2Health News:New tool helps identify prostate cancer patients with highest risk of death 2Health News:Practical play: Interactive video games appear valuable for ICU patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: